南方医科大学学报

南方医科大学学报 ›› 2016, Vol. 36 ›› Issue (09): 1291-.

• • 上一篇    下一篇

利妥昔单抗联合调整剂量EPOCH方案治疗胃肠道弥漫大B细胞淋巴瘤

胡蓉华，孙婉玲，赵弘，惠吴函，郭轶先，万岁桂，苏力   

  • 出版日期:2016-09-20 发布日期:2016-09-20

Rituximab combined with EPOCH regimen for treatment of diffuse large B cell lymphoma of the gastrointestinal tract: analysis of 4 cases

  • Online:2016-09-20 Published:2016-09-20

HTML

PDF

825

摘要： 通过对4例累及胃肠道的弥漫大B细胞淋巴瘤患者的发病经过、临床与病理特点、预后判断等方面进行综合分析，确定采 用利妥昔单抗联合调整剂量的EPOCH（R-DA-EPOCH）治疗方案，对患者化疗后的治疗反应和转归情况进行了评价随访。除1 例合并糖尿病、高血压多年的患者因出现严重感染死亡外，其他3例患者均获得完全缓解。将R-DA-EPOCH方案用于胃肠道弥 漫大B细胞淋巴瘤的一线治疗，具有较好的近期疗效，需要扩大样本量来判断其远期疗效。

Abstract: We treated 4 with a diagnosis of diffuse large B cell lymphoma involving the gastrointestinal tract with rituximab combined with adjusted dose EPOCH (R-DA-EPOCH) scheme based on a comprehensive analysis of the onset process, clinical and pathological features, and prognosis of the patients, and evaluated their treatment response. Complete remission (CR) was achieved in 3 patients after the treatment and 1 patient with diabetes and hypertension died due to severe infection. R-DA-EPOCH regimen as the first-line treatment of gastrointestinal diffuse large B cell lymphoma has a good short-term efficacy, but its long-term efficacy awaits further evaluation in future studies with larger sample sizes.